Antibody-drug conjugate

Veterinary Electrosurgery Market worth $120 million | MarketsandMarkets

Retrieved on: 
Tuesday, October 10, 2023
Control, Integra, Partnership, Acquisition, DACH, Bleeding, Risk, Animal, DRE, Coagulation, Olympus Corporation, Integra LifeSciences, Blood, Trauma, Anesthesia, Scar, Infection, Antibody-drug conjugate, Veterinarian, Tissue, Electrosurgery, Veterinary medicine, Symmetry, Medical device, Birth control, Dentistry, Medtronic

In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).

Key Points: 
  • In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).
  • Minimally Invasive: Electrosurgery is often minimally invasive, resulting in smaller incisions, less pain, and reduced scarring for animals post-surgery.
  • Versatility: Electrosurgical instruments can be adapted for various veterinary procedures, including soft tissue surgeries, dermatological treatments, and ophthalmic surgeries, making them versatile tools in veterinary medicine.
  • Enhanced Patient Outcomes: Overall, the advantages of electrosurgery contribute to improved patient outcomes, making it a valuable tool for modern veterinary practices and promoting the well-being of animals.

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Boehringer, Glomus tumor, American Society of Clinical Oncology, OBT, Fast Track, SCLC, ASCO, U.S. FDA, Boehringer Ingelheim, DLL3, Patient, Antibody-drug conjugate, Annual general meeting, Drug discovery, Diagnosis, ADC, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Disease, Pharmaceutical industry

BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for treatment of patients with SCLC and other neuroendocrine tumors that is being developed by Boehringer Ingelheim.

Key Points: 
  • BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for treatment of patients with SCLC and other neuroendocrine tumors that is being developed by Boehringer Ingelheim.
  • Encouraging data were presented from the Phase I first-in-human dose-escalation trial at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
  • These Phase I data demonstrated a clinically acceptable safety profile and early efficacy in patients with DLL3-positive ES-SCLC and epNECs.
  • This is tremendously exciting for OBT, as it shows the real impact this partnership has for patients in need.

ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023

Retrieved on: 
Thursday, September 28, 2023
San Diego Convention Center, Society, Therapy, Cancer, SITC, Immunotherapy, PDT, Conjugation, ADC, Poster, Patient, Antibody-drug conjugate, Fine chemical, Vaccine, Communications satellite

SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (Rina-S) and PRO1160, at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023), to be held at the San Diego Convention Center and virtually November 1-5, 2023.

Key Points: 
  • SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (Rina-S) and PRO1160, at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023), to be held at the San Diego Convention Center and virtually November 1-5, 2023.
  • Abstract #708: A Phase 1/2 Study of Rinatabart Sesutecan (PRO1184), a Novel Folate Receptor Alpha-Directed Antibody-Drug Conjugate, in Patients with Locally Advanced and/or Metastatic Solid Tumors
    Date and Location: Saturday, November 4, 2023, Exhibit Halls A and B1, 9 a.m. to 8:30 p.m. PDT
    Abstract #718: Phase 1/2 Study of PRO1160, a CD70-Directed Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors and Hematologic Malignancies
    Date and Location: Saturday, November 4, 2023, Exhibit Halls A and B1, 9 a.m. to 8:30 p.m. PDT
    Date and Location: Saturday, November 4, 2023, Exhibit Halls A and B1, 9 a.m. to 8:30 p.m. PDT
    Date and Location: Friday, November 3, 2023, Exhibit Halls A and B1, 9 a.m. to 7:00 p.m. PDT

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Retrieved on: 
Wednesday, August 23, 2023
P.C, Therapy, Par value, Vassar College, Pfizer, Sidley Austin, Antibody, Research and development, Development, Acquisition, Patient, Oncology nursing, CD40, Ladenburg Thalmann, Cancer, Conjugation, FACT, ADC, Wilson Sonsini Goodrich & Rosati, Antibody-drug conjugate, Cornell University, Fine chemical, Management, New York University, Philosophy

BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) (“Pyxis Oncology” or the “Company”), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the successful completion of its acquisition of Apexigen, Inc. (“Apexigen”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million. The combined company is positioned at the forefront of ADC innovation with a platform that now includes four key components: novel humanized antibody generation capabilities, an expanded library of linkers with improved stability, site specific conjugation chemistries, and optimized payloads.

Key Points: 
  • Xiaodong Yang, M.D., Ph.D., founder and former Chief Executive Officer of Apexigen, is joining the combined company as Distinguished Research Fellow.
  • With the closing of this transaction, Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, was appointed as an Independent Director to the Pyxis Oncology Board of Directors.
  • “I’m pleased to join the Pyxis Oncology Board of Directors,” said Jakob Dupont.
  • Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of common stock outstanding.

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

Retrieved on: 
Tuesday, July 25, 2023
Business development, IPO, University, SVKM's NMIMS, Therapy, Atlas Venture, MBA, Kellogg School, History, Sale, CAR, Virginia School for Girls, MD, Patient, CBO, Brown University, Broad arrow, Wilderness medicine, Conjugation, ADC, Cyrus, University of Virginia School of Medicine, Spacecraft, Bluebird bio, Antibody-drug conjugate, Northwestern University, Pharmaceutical industry, Novartis

LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.
  • Dr. Mozayeni joins Pheon with over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics.
  • Jeff Albers, Chairman of Pheon Therapeutics, commented: "Cyrus' extensive experience and a proven track record, make him the ideal person to guide Pheon through our next stage of Company growth.

Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer

Retrieved on: 
Tuesday, July 25, 2023
Business development, IPO, University, SVKM's NMIMS, Therapy, Atlas Venture, MBA, Kellogg School, History, Sale, CAR, Virginia School for Girls, MD, Patient, CBO, Brown University, Broad arrow, Wilderness medicine, Conjugation, ADC, Cyrus, University of Virginia School of Medicine, Spacecraft, Bluebird bio, Antibody-drug conjugate, Northwestern University, Pharmaceutical industry, Novartis

LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., July 25, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer.
  • Dr. Mozayeni joins Pheon with over 20 years of experience in the biotechnology industry and a strong history of driving strategic business growth.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "Pheon has a uniquely differentiated and preclinically validated approach to discovering and developing ADC therapeutics.
  • Jeff Albers, Chairman of Pheon Therapeutics, commented: "Cyrus' extensive experience and a proven track record, make him the ideal person to guide Pheon through our next stage of Company growth.

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
Thursday, July 13, 2023
State University of New York, AACR, EAP, GCC, Half-life, HPHA, ATAC, SRC, Binghamton University, Multiple myeloma, Clinical trial, State university system, Bone marrow, Cancer, American Association for Cancer Research, FSE, Magenta, Research, ATACS, Sale, Spanish mythology, Amanitin, Data analysis, CAIX, Patient, Antibody-drug conjugate, Microsoft Access, Marketing, CFO, Management, Ethics, ADC, Eli Lilly and Company, Depreciation, Spacecraft, Phase, FDA, Therapy, Market Access Program, Safety, Disease, Pharmaceutical industry, Vaccine, Fine chemical, Generic drug, Cryptocurrency, Telix, Emergence

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics

Retrieved on: 
Thursday, July 6, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Therapy, Antibody, Medication, HKEX, Amblyomma integrum, Broad arrow, Conjugation, ADC, Spacecraft, Antibody-drug conjugate, Fine chemical, Pharmaceutical industry

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.
  • Under the terms of the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary RenMice™ platforms.
  • Biocytogen will receive an upfront payment and is eligible for development and commercial milestone payments, as well as single-digit royalties on net sales.
  • Dr. Yuelei Shen, President and CEO of Biocytogen, said: "We are glad to collaborate with Pheon Therapeutics.

Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics

Retrieved on: 
Wednesday, July 5, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Antibody, Medication, HKEX, Amblyomma integrum, Broad arrow, Conjugation, ADC, Spacecraft, Antibody-drug conjugate, Fine chemical, Pharmaceutical industry

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.
  • Under the terms of the agreement, Pheon will develop and commercialize an antibody developed using Biocytogen’s proprietary RenMice™ platforms.
  • Biocytogen will receive an upfront payment and is eligible for development and commercial milestone payments, as well as single-digit royalties on net sales.
  • Dr. Yuelei Shen, President and CEO of Biocytogen, said: "We are glad to collaborate with Pheon Therapeutics.

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field

Retrieved on: 
Tuesday, May 16, 2023
Area studies, Partnership, Freedom, Astellas Pharma, Backbone, Sony, Enzyme, Type, Research, Cell, Solubility, Aggregation, Patient, OBI Pharma, Inc., Drug discovery, Conjugation, Biology, ADC, DAR, Antibody-drug conjugate, TSE, Fine chemical, Pharmaceutical industry

TOKYO, May 16, 2023 /PRNewswire/ -- Sony Corporation (President and CEO: Kimio Maki, "Sony") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC)*1 platform in oncology based on Sony's unique polymeric material, "KIRAVIATM*2 Backbone*3." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which conjugate antibodies and drugs is considered to be a key to the development of a better-performing ADC. This collaborative research leverages the flexibility in design and resulting properties such as high capacity and solubility of KIRAVIA Backbone as a linker of ADC, to effectively deliver anti-cancer drugs to targeted cells in a stable manner, aiming to further enhance therapeutic efficacy by achieving high Drug-to-Antibody Ratio (DAR), etc.

Key Points: 
  • " ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells.
  • The technology to create linkers which conjugate antibodies and drugs is considered to be a key to the development of a better-performing ADC.
  • The two companies jointly began exploratory research of new linker technology aimed at creating a new ADC platform in July 2022, and the expected profile was obtained in feasibility studies using human cancer cells.
  • Under this agreement, Sony and Astellas will jointly develop and optimize a new ADC platform using the KIRAVIA Backbone as a linker.